SHIGERU has invested €8 million in Azalea Vision's Series A funding round to support the development of smart contact lenses for light sensitivity and eye disease treatment.

Target Information

In July 2021, SHIGERU participated in an €8 million Series A funding round aimed at supporting Azalea Vision's development of smart contact lenses designed for light sensitivity and eye disease treatments. Azalea Vision is a pioneering company focused on innovative solutions in ocular health, leveraging advanced technology to address unmet medical needs in eye care.

These smart contact lenses are anticipated to significantly enhance the quality of life for individuals suffering from various eye conditions. By combining technology with medical therapies, Azalea Vision aims to deliver effective and user-friendly solutions to patients.

Industry Overview

The eye care industry in Europe is witnessing substantial growth, driven by advancing technologies and an increasing prevalence of eye disor

View Source

Similar Deals

zwei.7 Avelios

2025

Series A Healthcare Facilities & Services (NEC) Other
Demeter Phagos

2025

Series A Bio Therapeutic Drugs Other
China Development Industrial Bank Anbogen Therapeutics

2024

Series A Proprietary & Advanced Pharmaceuticals Other
比翼生醫 梅科科技

2024

Series A Hospitals, Clinics & Primary Care Services Other
Taiwania Capital Syncell

2024

Series A Biotechnology & Medical Research (NEC) Other
1000Farmacie 1000Farmacie

2023

Series A Telemedicine Services Other

SHIGERU

invested in

Azalea Vision

in 2021

in a Series A deal

Disclosed details

Transaction Size: $8M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert